Developing priority product groups as growth drivers

「The Group’s results benefited from growth in Uptravi, a treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, royalty income from overseas sales of the product, and Fintepla, a treatment for epileptic seizures associated with Dravet syndrome and Lennox-Gastaut syndrome, among others. In addition, Erleada, a treatment for prostate cancer recorded as product sales from October 2025 under a contract amendment, contributed to revenue of ¥170.771 billion, up 6.6% from the previous fiscal year.」

「加えて、契約改定に基づき2025年10月より当社の製品売上として計上している前立腺癌治療剤「アーリーダ」も寄与し、売上収益は1,707億7千1百万円と対前期比6.6%の増収となりました。」

「In the pharmaceuticals business, despite the impact of drug price revisions and generic products, sales of Uptravi, a treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, royalty income from overseas sales of the product, and Fintepla, a treatment for epileptic seizures associated with Dravet syndrome and Lennox-Gastaut syndrome, among others, increased. Revenue was ¥68.561 billion, up 0.1% from the same period of the previous year.」

「The Group’s operating results benefited from growth in Uptravi, a treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, royalty income from overseas sales of the product, and Viltepso, a treatment for Duchenne muscular dystrophy, among others. In addition, Vyxeos, a treatment for high-risk acute myeloid leukemia launched in May 2024, and other products contributed to revenue of ¥160.232 billion, up 8.1% from the previous fiscal year.」

「In the pharmaceuticals business, despite the impact of drug price revisions and generic products, sales of Uptravi, a treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, royalty income from overseas sales of the product, and Viltepso, a treatment for Duchenne muscular dystrophy, among others, increased. In addition, Vyxeos, a treatment for high-risk acute myeloid leukemia launched in May, and other products contributed to revenue of ¥68.496 billion, up 12.3% from the same period of the previous year.」

「To grow beyond the coming patent cliff for Uptravi, the company is advancing its pharmaceuticals and functional foods businesses under the “three key themes”: ① developing growth drivers to replace Uptravi, ② expanding global operations, and ③ continuously expanding the pipeline.」

「In the pharmaceuticals business, despite the impact of drug price revisions and generic products, sales of Uptravi, a treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, royalty income from overseas sales of the product, and Viltepso, a treatment for Duchenne muscular dystrophy, among others, increased. Revenue was ¥94.606 billion, up 1.6% from the same period of the previous year.」

「In the pharmaceuticals business, despite the impact of drug price revisions and generic products, sales of Uptravi, a treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, royalty income from overseas sales of the product, and Viltepso, a treatment for Duchenne muscular dystrophy, among others, increased. Revenue was ¥60.988 billion, up 0.8% from the same period of the previous year.」

「In the pharmaceuticals business, despite the impact of drug price revisions and generic products, sales of Viltepso, a treatment for Duchenne muscular dystrophy, Uptravi, a treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, and royalty income from overseas sales of the latter, among others, increased. Revenue was ¥30.87 billion, up 1.5% from the same period of the previous year.」

「In the pharmaceuticals business, despite the impact of drug price revisions and the reversal of a one-time gain from the sale of a priority review voucher, sales of Uptravi, royalty income from overseas sales of the product and Viltepso, among others, increased. Revenue was ¥121.988 billion, up 1.1% from the previous fiscal year.」

「In the pharmaceuticals business, although sales of Viltepso, a treatment for Duchenne muscular dystrophy, Uptravi, a treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, and royalty income from overseas sales of the latter, among others, increased, revenue declined due to the impact of drug price revisions and the reversal of a one-time gain from the sale of a priority review voucher. Revenue was ¥60.499 billion, down 4.6% from the same period of the previous year.」

「In the pharmaceuticals business, sales of Vidaza, a treatment for myelodysplastic syndromes and acute myeloid leukemia, Uptravi, a treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, and royalty income from overseas sales of the latter, among others, increased. In addition, proceeds from the sale of a priority review voucher issued by the U.S. Food and Drug Administration (FDA), as well as Viltepso, a treatment for Duchenne muscular dystrophy launched in May 2020 in Japan and August 2020 in the United States, contributed to sales of ¥93.625 billion, an increase of 16.7% from the same period of the previous year.」

「In the pharmaceuticals business, sales of Vidaza, a treatment for myelodysplastic syndromes and acute myeloid leukemia, Uptravi, a treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, and royalty income from overseas sales of the latter, among others, increased. In addition, proceeds from the sale of a priority review voucher issued by the U.S. Food and Drug Administration (FDA), as well as Viltepso, a treatment for Duchenne muscular dystrophy launched in May 2020 in Japan and August 2020 in the United States, contributed to sales of ¥63.43 billion, an increase of 26.1% from the same period of the previous year.」

「In the pharmaceuticals business, sales of Vidaza, a treatment for myelodysplastic syndromes and acute myeloid leukemia, Uptravi, a treatment for pulmonary arterial hypertension, royalty income from overseas sales of the latter, and Defitelio, a treatment for sinusoidal obstruction syndrome, among others, increased. In addition, proceeds from the sale of a priority review voucher issued by the U.S. Food and Drug Administration (FDA), as well as Viltepso, a treatment for Duchenne muscular dystrophy launched in May in Japan and August in the United States last year, contributed to sales of ¥37.05 billion, an increase of 41.4% from the same period of the previous year.」

「In the pharmaceutical business, royalty income from overseas sales of Uptravi, sales of Defitelio, a treatment for sinusoidal obstruction syndrome, Gazyva, a treatment for CD20-positive follicular lymphoma, and new product groups including Uptravi, together with co-promotion income, increased. In addition, milestone income from Uptravi and Viltepso, a treatment for Duchenne muscular dystrophy launched in Japan in May and the United States in August last year, contributed to net sales of ¥106.478 billion, an increase of 4.8% compared with the previous fiscal year.」

「In the pharmaceutical business, royalty income from overseas sales of Uptravi, Defitelio, a treatment for sinusoidal obstruction syndrome, Gazyva, a treatment for CD20-positive follicular lymphoma, sales of new product groups including Uptravi, and co-promotion income increased. In addition, milestone income from Uptravi and Viltepso, a treatment for Duchenne muscular dystrophy launched in Japan in May and the United States in August last year, contributed to net sales of ¥80.243 billion, an increase of 4.7% year on year.」

「In the pharmaceutical business, sales of Uptravi, royalty income from its overseas sales, Gazyva, a treatment for CD20-positive follicular lymphoma, and co-promotion income increased. In addition, Defitelio, a treatment for sinusoidal obstruction syndrome launched in September 2019, contributed to net sales of ¥50.296 billion, an increase of 1.0% year on year.」

「In the pharmaceutical business, sales of Uptravi, royalty income from its overseas sales, Gazyva, a treatment for CD20-positive follicular lymphoma, and co-promotion income increased. In addition, Defitelio, a treatment for sinusoidal obstruction syndrome launched in September 2019, contributed to net sales of ¥26.209 billion, an increase of 2.2% year on year.」

「In the pharmaceutical business, revenue from industrial property rights and other sources declined compared with the same period of the previous year, when milestone income was recorded from Uptravi, an in-house-developed treatment for pulmonary arterial hypertension. However, growth in domestic sales of Uptravi, Vidaza, a treatment for myelodysplastic syndromes, and Zalutia, a treatment for urinary disorders associated with benign prostatic hyperplasia, together with Gazyva, a treatment for CD20-positive follicular lymphoma launched jointly with CHUGAI PHARMACEUTICAL CO.,LTD. in August 2018, contributed to net sales of ¥76.665 billion, an increase of 1.1% year on year.」

「In the pharmaceutical business, domestic sales of Uptravi, an in-house-developed treatment for pulmonary arterial hypertension, royalty income from its overseas sales, Vidaza, a treatment for myelodysplastic syndromes, and Zalutia, a treatment for urinary disorders associated with benign prostatic hyperplasia, increased. In addition, Gazyva, a treatment for CD20-positive follicular lymphoma launched jointly with CHUGAI PHARMACEUTICAL CO.,LTD. in August last year, contributed to net sales of ¥49.817 billion, an increase of 8.1% year on year.」

「In the pharmaceutical business, domestic sales of Uptravi, an in-house-developed treatment for pulmonary arterial hypertension, royalty income from its overseas sales, Vidaza, a treatment for myelodysplastic syndromes, and Zalutia, a treatment for urinary disorders associated with benign prostatic hyperplasia, increased. In addition, Gazyva, a treatment for CD20-positive follicular lymphoma launched jointly with CHUGAI PHARMACEUTICAL CO.,LTD. in August last year, contributed to net sales of ¥25.652 billion, an increase of 6.6% year on year.」

「In the pharmaceutical business, sales of Uptravi, an in-house-developed treatment for pulmonary arterial hypertension, Zalutia, a treatment for urinary disorders associated with benign prostatic hyperplasia, Cialis, a treatment for erectile dysfunction, and royalty and co-promotion income from overseas sales of Uptravi increased. In addition, sales of Gazyva, a treatment for CD20-positive follicular lymphoma jointly launched with CHUGAI PHARMACEUTICAL CO.,LTD. in August last year, and milestone income from Uptravi contributed to net sales of ¥75.798 billion, an increase of 13.1% year on year.」

「In the pharmaceutical business, growth in Uptravi, an in-house-developed treatment for pulmonary arterial hypertension, Zalutia, a treatment for urinary disorders associated with benign prostatic hyperplasia, and Cialis, a treatment for erectile dysfunction, together with royalty and co-promotion income from overseas sales of Uptravi, contributed to net sales of ¥46.102 billion, an increase of 8.0% year on year.」

「In the pharmaceutical business, growth in Zalutia, a treatment for urinary disorders associated with benign prostatic hyperplasia, Adcirca, a treatment for pulmonary arterial hypertension, Tramal and OneTram, treatments for cancer and chronic pain, and Uptravi, an in-house-developed treatment for pulmonary arterial hypertension, together with royalty and co-promotion income from its overseas sales, contributed to net sales of ¥24.06 billion, an increase of 15.6% year on year.」

「In the pharmaceutical business, growth in Zalutia, Adcirca, Tramal and OneTram, and Uptravi, an in-house-developed treatment for pulmonary arterial hypertension launched in Japan in November 2016, and a substantial increase in royalty and co-promotion income from its overseas sales contributed to net sales of ¥67.003 billion, an increase of 1.7% year on year, despite the reversal of the benefit from the settlement of active pharmaceutical ingredient payments.」

「In the pharmaceutical business, growth in Zalutia, Vidaza, Tramal and OneTram, and Adcirca, together with growth in sales of Uptravi, an in-house-developed treatment for pulmonary arterial hypertension launched in Japan in November last year, and royalty income and other income from its overseas sales, contributed to net sales of ¥42.706 billion, an increase of 13.6% year on year.」

「In the pharmaceutical business, although sales of long-listed products declined, growth in Zalutia, a treatment for urinary disorders associated with benign prostatic hyperplasia, Vidaza, a treatment for myelodysplastic syndromes, Tramal and OneTram, treatments for cancer and chronic pain, and Adcirca, a treatment for pulmonary arterial hypertension, together with growth in sales of Uptravi, an in-house-developed treatment for pulmonary arterial hypertension launched in Japan in November last year, and royalty income from its overseas sales, contributed to net sales of ¥20.814 billion, an increase of 2.2% year on year.」

「Although sales of long-listed products declined, growth in Zalutia, a treatment for urinary disorders associated with benign prostatic hyperplasia, Vidaza, a treatment for myelodysplastic syndromes, Tramal and OneTram, treatments for cancer and chronic pain, and Adcirca, a treatment for pulmonary arterial hypertension, together with Uptravi, an in-house-developed treatment for pulmonary arterial hypertension launched in November 2016 and jointly developed in Japan with Actelion Pharmaceuticals Japan株式会社, contributed to net sales of ¥85.315 billion, an increase of 21.0% compared with the previous consolidated fiscal year. The above-mentioned upfront and royalty income and active pharmaceutical ingredient sales also contributed.」

「In the pharmaceutical business, growth in sales of new product groups, including Zalutia, a treatment for urinary disorders associated with benign prostatic hyperplasia, Vidaza, a treatment for myelodysplastic syndromes, Tramal and OneTram, treatments for cancer and chronic pain, and Adcirca, a treatment for pulmonary arterial hypertension, together with the above-mentioned upfront and royalty income and active pharmaceutical ingredient sales, contributed to net sales of ¥65.868 billion, an increase of 24.6% year on year.」

「In the pharmaceutical business, growth in sales of new product groups, including Zalutia, a treatment for urinary disorders associated with benign prostatic hyperplasia, Vidaza, a treatment for myelodysplastic syndromes, Tramal and OneTram, treatments for cancer and chronic pain, and Adcirca, a treatment for pulmonary arterial hypertension, together with the above-mentioned upfront and royalty income, contributed to net sales of ¥37.582 billion, an increase of 16.6% year on year.」

「In the pharmaceutical business, growth in sales of new product groups, including Zalutia, a treatment for urinary disorders associated with benign prostatic hyperplasia, Vidaza, a treatment for myelodysplastic syndromes, Adcirca, a treatment for pulmonary arterial hypertension, and Tramal and OneTram, treatments for cancer and chronic pain, together with the above-mentioned upfront and royalty income, contributed to net sales of ¥20.364 billion, an increase of 28.9% year on year.」

「In sales, we will invest management resources in priority fields, maximize the value of our pharmaceuticals, and develop 3 product groups, Zalutia, Vidaza and treatments for pulmonary arterial hypertension, as growth drivers.」